Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts
online as soon as possible after acceptance. Accepted manuscripts have been peer …

EYNOTE-045 was a phase 3 multicenter open-label randomized trial of the Programmed
Death 1 inhibitor pembrolizumab vs second-line chemotherapy in patients with advanced …

Purpose Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were
limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven …

Urothelial carcinoma is the sixth most common cancer type in the United States. Although
most patients present with early stage disease which is associated with improved outcomes …

Objectives The aim of this study was to analyze data and current trends in immune
checkpoint targeting therapy for bladder cancer. Data sources A systematic literature search …

Background: Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective for
treatment of recurrent, advanced urothelial cancer. Data from KEYNOTE-052 showed first …

The advent of targeted agents, such as enfortumab vedotin, erdafitinib, and sacituzumab
govitecan, have revolutionized the treatment of metastatic urothelial cancer. Although these …

Five new PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of
metastatic urothelial carcinoma (UC): pembrolizumab, atezolizumab, durvalumab …

With the advent of platinum-based chemotherapy, survival rates for metastatic urothelial
carcinoma have plateaued, giving way to the modern immunotherapy paradigm. Although …

Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and
metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12 …